ERO1L、MUC16在非小细胞肺癌组织中的表达及临床价值

Expression and clinical value of ERO1L and MUC16 in non-small cell lung cancer

目的探讨非小细胞肺癌(NSCLC)中内质网氧化还原酶1α(ERO1A)、细胞表面相关黏蛋白16(MUC16)表达及临床价值。方法以2018年2月至2019年2月于该院就诊的94例NSCLC患者为研究对象。应用荧光定量PCR及免疫组织化学检测癌组织及癌旁组织中ERO1A和MUC16 mRNA及蛋白表达,分析ERO1A、MUC16 mRNA表达与临床病理特征的关系。采用Kaplan-Meier生存曲线分析ERO1A、MUC16 mRNA表达与NSCLC患者预后的关系,单因素及多因素COX回归分析影响NSCLC患者生存预后的因素。结果NSCLC癌组织中ERO1A、MUC16 mRNA表达水平均明显高于癌旁组织,差异有统计学意义(t=34.472、22.528,均P<0.05)。Pearson相关性分析结果显示,NSCLC中ERO1A与MUC16 mRNA表达呈正相关(r=0.610,P<0.001)。免疫组织化学法检测结果显示,ERO1A和MUC16蛋白均位于细胞膜和细胞质,NSCLC癌组织中ERO1A和MUC16蛋白阳性率明显高于癌旁组织,差异有统计学意义(χ^(2)=143.323、153.741,均P<0.001)。ERO1A mRNA表达与肿瘤分期、淋巴结转移有关(P<0.05),MUC16 mRNA表达与肿瘤分期、病理分级及淋巴结转移有关(P<0.05)。ERO1A mRNA高表达组患者累积生存明显低于低表达组(Log-rankχ^(2)=8.776,P=0.003),MUC16 mRNA高表达组患者累积生存明显低于低表达组(Log-rankχ^(2)=8.003,P=0.005)。肿瘤分期Ⅲ期、伴淋巴结转移、ERO1A及MUC16 mRNA高表达影响NSCLC患者生存预后的独立危险因素。结论NSCLC癌组织中ERO1A、MUC16表达升高,是影响NSCLC患者生存预后的独立危险因素,二者表达升高与NSCLC患者不良临床病理特征及预后有关。

Objective To investigate the expression and clinical value of endoplasmic reticulum oxidoreductase 1α(ERO1A)and cell surface-associated mucin 16(MUC16)in non-small cell lung cancer(NSCLC).Methods A total of 94 patients with NSCLC treated in this hospital from February 2018 to February 2019 were selected as the research objects.The mRNA and protein expressions of ERO1A and MUC16 in cancer tissues and adjacent tissues were detected by fluorescence quantitative PCR and immunohistochemistry.The relationship between ERO1A and MUC16 mRNA expression and clinicopathological characteristics in NSCLC was analyzed.In addition,Kaplan-Meier survival curve was used to analyze the relationship between ERO1A,MUC16 mRNA expression and prognosis of NSCLC patients.Univariate and multivariate COX regression analysis was performed to analyze the factors affecting survival and prognosis of NSCLC patients.Results The mRNA expressions of ERO1A and MUC16 in NSCLC tissues were significantly higher than those in adjacent tissues(t=34.472,22.528,both P<0.05).Pearson correlation analysis showed that ERO1A positively correlated with MUC16 mRNA expression in NSCLC(r=0.610,P<0.001).Immunohistochemical tests showed that ERO1A and MUC16 proteins were both located in the cell membrane and cytoplasm,and the positive rates of ERO1A and MUC16 proteins in NSCLC cancer tissues were significantly higher than those in adjacent tissues,with statistical significance(χ^(2)=143.323,153.741,both P<0.001).ERO1A mRNA expression was related to tumor stage and lymph node metastasis(P<0.05),and MUC16 mRNA expression was related to tumor stage,pathological grade and lymph node metastasis(P<0.05).The cumulative survival of patients in the ERO1A mRNA high expression group was significantly lower than that in the low expression group(Log-rankχ^(2)=8.776,P=0.003),and the cumulative survival of patients in the MUC16 mRNA high expression group was significantly lower than that in the low expression group(Log-rankχ^(2)=8.003,P=0.005).Tumor stageⅢ,lymph node metastasis,ERO1A and MUC16 mRNA high expression were independent risk factors for survival and prognosis of NSCLC patients.Conclusion The increased expressions of ERO1A and MUC16 in NSCLC cancer tissues are associated with adverse clinicopathological features and prognosis of patients with NSCLC,which are independent risk factors affecting survival and prognosis of NSCLC patients.